(Image Credits: Pixabay) Merck on Tuesday announced that it has signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion. The deal will give the U.S. drugmaker access to an ...

Thus, I believe that Merck has great potential to strengthen its position in the global cancer therapeutics market, which, as I mentioned in the article "Top 5 Cancer Pharma Stocks With Strong ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Daily Merck & Company, Inc. Dow pharmaceutical components are leading overall index losses. Merck emerged as the biggest decliner, down 4.6%, while Amgen shed 4.3% and Johnson & Johnson lost 4.1%.

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said ... Small-town Ireland nervous as Trump seeks to lure pharma investment to US 7:16 AM UTC Healthcare & Pharmaceuticalscategory ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday, AZ ...